The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton ...

The MarketWatch News Department was not involved in the creation of this content. ATR-01, which uses a filaggrin-secreting strain of S. epidermidis, is in preclinical development for ichthyosis ...

This localized campaign demonstrates ATR’s commitment to making secure, sustainable, and cost-effective IT asset management more accessible to new clients in the region. The new program enables ...

BRANFORD, Conn., Aug. 27, 2025 /PRNewswire/ -- Azitra, Inc. (AZTR) ("Azitra"), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today ...

Azitra (AZTR) is developing ATR04-484 for the treatment of EGFR inhibitor-associated rash with plans to dose first patient in Phase 1/2 trial in the first half of 2025 BRANFORD, Conn., April 25, 2025 ...

BRANFORD, Conn., Oct. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, ...

PENSACOLA, Fla., June 23, 2025 (GLOBE NEWSWIRE) -- Advanced Technology Recycling (ATR), a national leader in IT asset disposition (ITAD) and R2v3/RIOS certified electronics recycling, is excited to ...

Azitra is developing ATR04-484 for the treatment of EGFR inhibitor-associated rash with plans to dose first patient in Phase 1/2 trial in the first half of 2025 "We look forward to presenting an ...